Bausch Health Completes Acquisition of DURECT Corporation
September 11, 2025
Bausch Health Companies Inc. completed its previously announced tender offer to acquire DURECT Corporation for $1.75 per share in cash, totaling about $63 million upfront. The deal also includes potential net sales milestone payments of up to $350 million in the aggregate related to larsucosterol, which expands Bausch Health’s hepatology pipeline for alcohol-associated hepatitis.
- Buyers
- Bausch Health Companies Inc., Bausch Health Americas, Inc., BHC Lyon Merger Sub, Inc.
- Targets
- DURECT Corporation
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.